Core Viewpoint - Changfeng Pharmaceutical (02652) has successfully listed its shares at a price of HKD 14.75 per share, raising approximately HKD 525 million, with a significant initial trading increase of 218.64% to HKD 47 per share [1] Company Overview - Changfeng Pharmaceutical focuses on the research, development, production, and commercialization of inhalation technology and inhalation drugs, primarily targeting respiratory diseases [1] - The company has developed a diverse product portfolio that addresses a wide range of patients, medical specialties, and treatment areas [1] Regulatory Approvals and Market Performance - The company has received six product approvals from the National Medical Products Administration (NMPA) of China and the U.S. Food and Drug Administration (FDA), demonstrating its capabilities in clinical development, production, regulatory affairs, and commercialization [1] - CF017, an inhalation suspension of budesonide for the treatment of bronchial asthma, is the company's first approved product and has quickly gained market traction since its approval in May 2021 [1] Market Position - CF017 has been included in China's centralized procurement plan, leading to significant market growth [1] - According to Frost & Sullivan, CF017 is projected to capture approximately 16% of the Chinese budesonide inhalation drug market by 2024, based on sales volume [1]
新股首日 | 长风药业(02652)首挂上市 早盘高开218.64% 公司专注于吸入技术及吸入药物领域